Treatment Outcomes of Immune-Related Cutaneous Adverse Events

PURPOSE: The aim of the current study was to report the efficacy of topical and systemic treatments for immune-related cutaneous adverse events (ircAEs) attributed to checkpoint inhibitors in an uncontrolled cohort of patients referred to oncodermatology clinics. METHODS: A retrospective analysis of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Phillips, Gregory S., Wu, Jennifer, Hellmann, Matthew D., Postow, Michael A., Rizvi, Naiyer A., Freites-Martinez, Azael, Chan, Donald, Dusza, Stephen, Motzer, Robert J., Rosenberg, Jonathan E., Callahan, Margaret K., Chapman, Paul B., Geskin, Larisa, Lopez, Adriana T., Reed, Vanessa A., Fabbrocini, Gabriella, Annunziata, Maria Carmela, Kukoyi, Oluwaseun, Pabani, Aliyah, Yang, Chih-Hsun, Chung, Wen-Hung, Markova, Alina, Lacouture, Mario E.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2019
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7001790/
https://ncbi.nlm.nih.gov/pubmed/31216228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.02141
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars